Furthermore, this study also provides a new mechanistic linking matrix stiffness-ACADL axis to lipid metabolic reprogramming and HCC progression, indicating that the ACADL-dependent mechanoresponsive pathway is a potential therapeutic target for HCC treatment. Here, ACADL is linked to hepatocellular carcinoma.